References
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674.
- Pitti RM, Marsters SA, Ruppert S, . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687–12690.
- Sprick MR, Weigand MA, Rieser E, . FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12: 599–609.
- Sprick MR, Rieser E, Stahl H, . Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 2002;21:4520–4530.
- Scaffidi C, Fulda S, Srinivasan S, . Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675–1687.
- Li H, Zhu H, Xu CJ, . Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491–501.
- Ashkenazi A, Pai RC, Fong S, . Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155–162.
- Testa U. TRAIL/TRAIL-R in hematologic malignancies. J Cell Biochem 2010;110:21–34.
- Kim EH, Kim SU, Shin DY, . Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004;23:446–456.
- Ortiz-Ferron G, Yerbes R, Eramo A, . Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 2008;18:664–676.
- Festa M, Petrella A, Alfano S, . R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-κB pathway. Int J Cancer 2009;124:2728–2736.
- Azevedo WF, Leclerc S, Meijer L, . Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1997;243:518–526.
- Bach S, Knockaert M, Reinhardt J, . Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005;280:31208–31219.
- Alvi AJ, Austen B, Weston VJ, . A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005;105:4484–4491.
- MacCallum DE, Melville J, Frame S, . Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005;65:5399–5407.
- Lacrima K, Valentini A, Lambertini C, . In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005;16:1169–1176.
- Hahntow IN, Schneller F, Oelsner M, . Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004;18:747–755.
- Lacrima K, Rinaldi A, Vignati S, . Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma 2007;48:158–167.
- Havlic ek L, Hanus J, Vesely J, . Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 1997;40:408–412.
- Oikonomou E, Koc M, Sourkova V, . Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One 2011;6:e21632.
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289–300.
- Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2008;4;44–57.
- Jin Z, Li Y, Pitti R, . Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009;137:721–735.
- Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001;60:785–789.
- Garrofé-Ochoa X, Cosialls A, Ribas J, . Transcriptional modulation of apoptosis regulators by roscovitine and related compounds. Apoptosis 2011;16:660–670.
- Certo M, Moore VDG, Nishino M, . Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351–365.
- Deng J, Carlson N, Takeyama K, . BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT- 737 and conventional chemotherapeutic agents. Cancer Cell 2007;12: 171–185.
- Meng XW, Lee S-H, Dai H, . MCL-1 as a buffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis. J Biol Chem 2007;282:29831–29846.